Biotech Drives Base Editing Into Clinic As Big Pharma Looks On

 
• By Ayisha Sharma

Base editing has reached a new milestone as Beam’s lead candidate gets the green light for clinical trials, and its peer Verve Therapeutics is not far behind, while big pharma dips its toes in the water.  

Base Editing Enables A Specific Base-Pair Change Without Breaking The DNA Double Strand. • Source: Alamy

More from Business

More from Scrip